5G-EMERALD: Amivantamab in Malignant Brain Tumours | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
5G-EMERALD: Amivantamab in Malignant Brain Tumours	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor	Active, not recruiting	Phase 1	2026-08-17		NCT06632236

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Cambridge University Hospitals NHS Foundation Trust	64
Cancer Research UK	59
Institute of Cancer Research, United Kingdom	59
Janssen Pharmaceutica N.V., Belgium	13
Minderoo Foundation	4
Royal Marsden NHS Foundation Trust	89
University of Cambridge	80

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cambridge University Hospitals	Cambridge	United Kingdom	4
The Royal Marsden Hospital - Drug Development Unit	Sutton	United Kingdom	2